These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 37961996)

  • 21. N6-methyladenosine RNA modification in cancer therapeutic resistance: Current status and perspectives.
    Xu Z; Peng B; Cai Y; Wu G; Huang J; Gao M; Guo G; Zeng S; Gong Z; Yan Y
    Biochem Pharmacol; 2020 Dec; 182():114258. PubMed ID: 33017575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. m6A/HOXA10-AS/ITGA6 axis aggravates oxidative resistance and malignant progression of laryngeal squamous cell carcinoma through regulating Notch and Keap1/Nrf2 pathways.
    Zhao K; Chen L; Xie Y; Ren N; Li J; Zhai X; Zheng S; Liu K; Wang C; Qiu Q; Peng X; Wang W; Liu J; Che Q; Fan J; Hu H; Liu M
    Cancer Lett; 2024 Apr; 587():216735. PubMed ID: 38369001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrophage M1 regulatory diabetic nephropathy is mediated by m6A methylation modification of lncRNA expression.
    Li C; Su F; Liang Z; Zhang L; Liu F; Fan W; Li Z
    Mol Immunol; 2022 Apr; 144():16-25. PubMed ID: 35168108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N6-methyladenosine (m6A) as a regulator of carcinogenesis and drug resistance by targeting epithelial-mesenchymal transition and cancer stem cells.
    Wang C; Danli Ma ; Yu H; Zhuo Z; Ye Z
    Heliyon; 2023 Mar; 9(3):e14001. PubMed ID: 36915498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. m6A modification on the fate of colorectal cancer: functions and mechanisms of cell proliferation and tumorigenesis.
    Jiang X; Jin Z; Yang Y; Zheng X; Chen S; Wang S; Zhang X; Qu N
    Front Oncol; 2023; 13():1162300. PubMed ID: 37152066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in crosstalk between N6-methyladenosine (m6A) modification and circular RNAs in cancer.
    Huang X; Guo H; Wang L; Yang L; Shao Z; Zhang W
    Mol Ther Nucleic Acids; 2022 Mar; 27():947-955. PubMed ID: 35211355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNA N6-methyladenosine: a new player in autophagy-mediated anti-cancer drug resistance.
    Paramasivam A; Priyadharsini JV
    Br J Cancer; 2021 May; 124(10):1621-1622. PubMed ID: 33723389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The m6A modification-mediated positive feedback between glycolytic lncRNA SLC2A1-DT and c-Myc promotes tumorigenesis of hepatocellular carcinoma.
    Zeng Z; Wang J; Xu F; Hu P; Hu Y; Zhuo W; Chen D; Han S; Wang F; Zhao Y; Huang Y; Zhao G
    Int J Biol Sci; 2024; 20(5):1744-1762. PubMed ID: 38481809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel insights into the interplay between m
    Yi YC; Chen XY; Zhang J; Zhu JS
    Mol Cancer; 2020 Aug; 19(1):121. PubMed ID: 32767982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of m6A methylation in therapy resistance in cancer.
    Zhuang H; Yu B; Tao D; Xu X; Xu Y; Wang J; Jiao Y; Wang L
    Mol Cancer; 2023 Jun; 22(1):91. PubMed ID: 37264402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ALKBH5-mediated m6A modification of lncRNA KCNQ1OT1 triggers the development of LSCC via upregulation of HOXA9.
    Li Y; Yan B; Wang X; Li Q; Kan X; Wang J; Sun Y; Wang P; Tian L; Liu M
    J Cell Mol Med; 2022 Jan; 26(2):385-398. PubMed ID: 34850551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging role of long non-coding RNAs in cancer chemoresistance: unravelling the multifaceted role and prospective therapeutic targeting.
    Singh D; Khan MA; Siddique HR
    Mol Biol Rep; 2020 Jul; 47(7):5569-5585. PubMed ID: 32601922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N6-methyladenosine (m6A)-mediated up-regulation of long noncoding RNA LINC01320 promotes the proliferation, migration, and invasion of gastric cancer via miR495-5p/RAB19 axis.
    Hu N; Ji H
    Bioengineered; 2021 Dec; 12(1):4081-4091. PubMed ID: 34288797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction between m6A and ncRNAs and Its Association with Diseases.
    Chen S; Dong J; Luo X; Nie Z; Lu S; Liu H; Liu J
    Cytogenet Genome Res; 2022; 162(4):171-187. PubMed ID: 36122561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Research progress of N6-methyladenosine in colorectal cancer: A review.
    Lin Y; Shi H; Wu L; Ge L; Ma Z
    Medicine (Baltimore); 2023 Nov; 102(47):e36394. PubMed ID: 38013272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic N6-methyladenosine modification of lncRNA modulated by METTL3 during bacterial disease development in an echinoderm.
    Zhang S; Shao Y; Li D; Li C
    Fish Shellfish Immunol; 2022 May; 124():497-504. PubMed ID: 35483599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel insights into the interplay between m6A modification and programmed cell death in cancer.
    Chen J; Ye M; Bai J; Hu C; Lu F; Gu D; Yu P; Tang Q
    Int J Biol Sci; 2023; 19(6):1748-1763. PubMed ID: 37063421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging roles of m6A RNA modification in cancer therapeutic resistance.
    Liu WW; Zhang ZY; Wang F; Wang H
    Exp Hematol Oncol; 2023 Feb; 12(1):21. PubMed ID: 36810281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Study on the Role and Mechanism of METTL3 Mediating the Up-regulation of 
m6A Modified Long Non-coding RNA THAP7-AS1 in Promoting the Occurrence of 
Lung Cancer].
    Zhang Y; Wang Y; Liu M
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):919-933. PubMed ID: 38163978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.